<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520686</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT2.023</org_study_id>
    <nct_id>NCT03520686</nct_id>
  </id_info>
  <brief_title>QUILT 2.023: A Study of N803 in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.</brief_title>
  <official_title>QUILT 2.023: A Phase 2, Open-Label, Randomized Study of N803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, open-label, randomized study to compare the safety and efficacy of
      combination therapy with N-803 and pembrolizumab (experimental arm) versus pembrolizumab
      alone (control arm), as first-line treatment for subjects with stage 3 or 4 advanced or
      metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Anticipated">April 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by RECIST Version 1.1 based on BICR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by RECIST Version 1.1 based on BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by RECIST Version 1.1 based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>2 Months</time_frame>
    <description>Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by iRECIST based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by iRECIST based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Defined by iRECIST based on BICR.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent AEs and SAEs</measure>
    <time_frame>24 Months</time_frame>
    <description>Graded using the NCI CTCAE Version 5.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentration of N-803</measure>
    <time_frame>24 Months</time_frame>
    <description>maximum observed concentration (Cmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity profile of N-803 in combination with pembrolizumab.</measure>
    <time_frame>24 Months</time_frame>
    <description>Detection of anti-drug antibodies</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor molecular profiles and correlations with subject outcomes</measure>
    <time_frame>9 Weeks</time_frame>
    <description>Genomic sequencing of tumor cells from tissue</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">388</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Pembrolizumab</intervention_name>
    <description>The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:
Day 1, every 3 weeks:
Pembrolizumab (200 mg intravenous infusion [IV])
N-803 (15 μg/kg subcutaneously [SC])</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:
Day 1, every 3 weeks:
• Pembrolizumab (200 mg IV)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old.

          2. Able to understand and provide a signed informed consent that fulfills the relevant
             IRB or Independent Ethics Committee (IEC) guidelines.

          3. Histologically-confirmed stage 3 or 4 NSCLC disease. Subjects with stage 3 disease
             must not be candidates for treatment with surgical resection or chemoradiation.

          4. Subjects must not have received prior systemic chemotherapy for advanced or metastatic
             NSCLC. Previous neoadjuvant/adjuvant chemotherapy is allowed if completed ≥ 6 months
             before diagnosis of metastatic disease.

          5. NSCLC tumors must have PD-L1 expression (i.e. a TPS ≥1%) as determined by an
             FDA-approved test.

          6. The subject's tumor must not harbor an EGFR sensitizing (activating) mutation or ALK
             translocation. EGFR sensitizing mutations are those mutations that are amenable to
             treatment with tyrosine kinase inhibitors including erlotinib, gefitinib, or afatinib.
             Investigators must be able to produce the source documentation of the EGFR mutation
             and ALK translocation status in all subjects with non-squamous histologies and for
             subjects in whom testing is clinically recommended. If either an EGFR sensitizing
             mutation of ALK translocation is detected, additional information regarding the
             mutation status of the other molecule is not required. If unable to test for these
             molecular changes, formalin fixed paraffin embedded tumor tissue of any age should be
             submitted to a central laboratory designated by the Sponsor for such testing. Subjects
             with non-squamous histologies will not be randomized until the EGFR mutation status
             and/or ALK translocation status is available in source documentation at the site. For
             patients enrolled who are known to have a tumor of predominantly squamous histology,
             molecular testing for EGFR and ALK translocation will not be required as this is not
             standard of care and is not part of current diagnostic guidelines.

          7. Life expectancy of ≥ 3 months.

          8. ECOG performance status of 0 or 1.

          9. Measurable tumor lesions according to RECIST 1.1.

         10. Must be willing to provide a tumor biopsy specimen 9 weeks after the start of
             treatment for exploratory analyses, if considered safe by the Investigator.

        10. Must be willing to release tumor biopsy specimen used for diagnosis of metastatic NSCLC
        (if available) for additional exploratory tumor molecular profiling.

        11. Must be willing to provide blood samples prior to the start of treatment on this study
        for exploratory research.

        12. Must be willing to provide a tumor biopsy specimen 9 weeks after the start of treatment
        for exploratory analyses, if considered safe by the Investigator.

        13. Ability to attend required study visits and return for adequate follow-up, as required
        by this protocol 14. Agreement to practice effective contraception for female subjects of
        child-bearing potential and non-sterile males. Female subjects of child-bearing potential
        must agree to use effective contraception for up to 1 year after completion of therapy, and
        non-sterile male subjects must agree to use a condom for up to 4 months after treatment.
        Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation),
        two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine
        devices (IUDs), hormonal therapy, and abstinence.

        Exclusion Criteria:

          1. Serious uncontrolled concomitant disease that would contraindicate the use of the
             investigational drug used in this study or that would put the subject at high risk for
             treatment-related complications.

          2. Tumors that harbor an EGFR sensitizing (activating) mutation or ALK translocation.

          3. A history of prior malignancy. Subjects with a history of basal or squamous cell
             carcinoma of the skin, superficial bladder cancer, or in situ cervical cancer, or
             those that have received curative therapy with no disease recurrence for ≥ 3 years,
             may be enrolled.

          4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's
             disease, or autoimmune disease associated with lymphoma).

          5. History of organ transplant requiring immunosuppression; or history of pneumonitis or
             interstitial lung disease requiring treatment with systemic steroids; or a history of
             receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days
             prior to study initiation. Daily steroid replacement therapy (eg, prednisone or
             hydrocortisone) and corticosteroid use to manage AEs are permitted.

          6. Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of
             study initiation.

          7. Requirement for other forms of anticancer treatment while on trial, including
             maintenance therapy, other radiation therapy, and/or surgery.

          8. Known CNS metastases or carcinomatous meningitis. Subjects with previously treated,
             stable CNS metastases (no evidence of progression for ≥ 4 weeks, and resolution of
             neurologic symptoms to baseline state) are permitted in this study.

          9. History of receiving a live vaccine 30 days prior to study treatment.

         10. History of human immunodeficiency virus (HIV), or known active hepatitis B or C
             infection.

         11. An active infection requiring systemic IV therapy.

         12. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis).

         13. Inadequate organ function, evidenced by the following laboratory results:

               1. Absolute neutrophil count &lt; 1,500 cells/mm3.

               2. Platelet count &lt; 100,000 cells/mm3.

               3. Total bilirubin greater the upper limit of normal (ULN; unless the subject has
                  documented Gilbert's syndrome).

               4. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])
                  &gt; 1.5 × ULN.

               5. Alkaline phosphatase (ALP) levels &gt; 2.5 × ULN.

               6. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L or creatinine clearance &lt; 40 mL/min
                  (using the Cockcroft-Gault formula)

         14. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or
             clinically significant (ie, active) cardiovascular disease, cerebrovascular
             accident/stroke, or myocardial infarction within 6 months prior to first study
             medication; unstable angina; congestive heart failure of New York Heart Association
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with
             uncontrolled hypertension should be medically managed on a stable regimen to control
             hypertension prior to study entry.

         15. Dyspnea at rest due to complications of advanced malignancy or other disease requiring
             continuous oxygen therapy.

         16. Known hypersensitivity to any component of the study medication(s).

         17. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug
             reaction with any of the study medications.

         18. Participation in an investigational drug study or history of receiving any
             investigational treatment within 30 days prior to screening for this study, except for
             testosterone-lowering therapy in men with prostate cancer.

         19. Assessed by the Investigator to be unable or unwilling to comply with the requirements
             of the protocol.

         20. Concurrent participation in any interventional clinical trial.

         21. Pregnant and nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Garner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Clinical Operations &amp; Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jayson Garmizo, MEng</last_name>
    <phone>310-912-2230</phone>
    <email>Jayson.Garmizo@ImmunityBio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke Greenley, BS</last_name>
    <phone>919-810-0367</phone>
    <email>Brooke.Greenley@Immunitybio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Urological Institute - Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sellers, RN, BSN, CCRC</last_name>
      <phone>501-624-7700</phone>
      <email>Laura.Sellers@aoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Sheila Slone, RN</last_name>
      <phone>501-624-7700</phone>
      <email>Sheila.Slone@aoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roy Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MemorialCare Health System</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Zuniga</last_name>
      <phone>714-378-7496</phone>
      <email>JZuniga@memorialcare.org</email>
    </contact>
    <investigator>
      <last_name>Amol Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Health Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>92106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Melendrez, CCRC</last_name>
      <phone>818-543-7574</phone>
      <email>MelendKM@ah.org</email>
    </contact>
    <investigator>
      <last_name>Mihran Shirinian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health South Florida - Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Garcia</last_name>
      <phone>786-594-7565</phone>
      <email>GiovanniG@baptisthealth.net</email>
    </contact>
    <contact_backup>
      <last_name>Mari Vega, BA, CCRC</last_name>
      <phone>786-527-8866</phone>
      <email>MariVe@baptisthealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>Federico Albrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health - Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karli Heasley</last_name>
      <phone>589-260-3196</phone>
      <email>Karli.Heasley@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Firas Badin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Dickerson</last_name>
      <phone>502-897-1166</phone>
      <email>Renee.Dickerson1@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Wangjian Zhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research Joplin</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmeralda Carrillo</last_name>
      <email>Esmeralda.Carrillo@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Samir M Dalia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Cancer &amp; Hematology - Chub O'Reilly Cancer Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly McLaughlin</last_name>
      <phone>406-238-6290</phone>
      <email>Kelly.McLaughlin@sclhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Duyck</last_name>
      <phone>406-238-6996</phone>
      <email>Heather.Ducyk@sclhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick W Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Jasek</last_name>
      <email>Amy_Jasek@URMC.Rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica E. Mackowiak</last_name>
      <email>Jessica_Ellis@URMC.Rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Mulford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Freeland, RN</last_name>
      <phone>405-752-3402</phone>
      <email>sheryl.freeland@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Carla Kurkjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LeHigh Valley</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Warner</last_name>
      <phone>713-334-4033</phone>
      <email>vwarner@gettysburgoncology.com</email>
    </contact>
    <investigator>
      <last_name>Satish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Leitner, MPH</last_name>
      <email>leitnera@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Godwin</last_name>
      <phone>843-792-8876</phone>
      <email>woodrufk@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Wrangle, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center/Bon Secours St. Francis Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Beckman</last_name>
      <email>melissa_beckman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Clinical Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Vogel</last_name>
      <phone>605-328-1373</phone>
      <email>Staci.Vogel@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Sumey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Byers, BSN, RN</last_name>
      <phone>865-305-7136</phone>
      <email>ebyers@utuck.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Kelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Williams</last_name>
      <phone>804-893-8717</phone>
      <email>Mary_Williams7@bshsi.orgry</email>
    </contact>
    <investigator>
      <last_name>William J Irvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pembrolizumab</keyword>
  <keyword>N-803</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

